BACKGROUND:
Analysis of circulating immune complexes (CICs) produced during an immune response may be useful in elucidating some aspects of this process. Identification of antigens incorporated into CICs provides information that may be helpful in developing diagnostic and treatment strategies for autoimmune diseases, infection, cancer, and transplantation therapy, and such information might be more relevant than information on free antigens. Because CICs may contain many antigens, comprehensive identification and profiling of such antigens is more effective than immunoblotting detection.
METHODS:
We developed a novel proteomic strategy (immune complexome analysis) in which immune complexes (ICs) are separated from serum, digested directly with trypsin, and then subjected to nano-liquid chromatography-tandem mass spectrometry for identifying and profiling antigens in CICs. We applied this strategy to the analysis of CICs in 21 rheumatoid arthritis (RA) patients. Serum samples from 13 healthy donors and 8 osteoarthritis patients were used as controls.
RESULTS:
CICs containing thrombospondin-1 (TSP-1) and platelet factor 4 (PF4) were found in the serum of 81% and 52% of RA patients, respectively, and in none of the controls.
CONCLUSIONS:
The ICs in the serum of a majority of the RA patients contained TSP-1 or PF4, and these ICs may have potential as alternative biomarkers. Our technique for immune complexome analysis uses routine clinical samples, simple protocols, and widely available equipment. This method may be generally applicable to the study of the relationship between CICs and certain diseases associated with the immune response in animals and humans.
Immune complexes (ICs) 8 are products of reactions that involve noncovalent interactions between foreign antigens or autoantigen and antibody molecules. Circulating ICs (CICs) are possibly pathogenic unless they are removed by phagocytosis. Importantly, the identification of antigens in CICs might be different from that of free antigens because CICs are the direct and real-time products of an immune response. For a long time, CICs were thought to represent a common pathway for the pathogenesis of a large variety of diseases (e.g., immunologic diseases); however, the relationship is still unclear. Therefore, information on antigens in CICs is useful to reveal whether CICs play an important role in a particular disease. In the future, such information might provide new insights into pathophysiology and could form the basis for novel diagnostic and treatment strategies for autoimmune diseases, infection, cancer, and transplantation therapy. CICs present in the human body are likely to contain many different antigens that could reflect underlying disease and/or differences between individuals. Therefore, comprehensive identification and profiling of such antigens might be more effective than immunoblotting detection of individual antigens. Microarrays are widely used to detect multiple antigens (1 ); however, the analytical comprehensiveness of this technique is fundamentally limited because preparation and selection of antigens or antibodies is required and because only molecules represented on microarrays can be identified. CICs and ICs in synovial fluid are likely to contribute to the pathogenesis of rheumatoid arthritis (RA) through the activation of the complement cascade, direct destruction of cartilage, and production of tumor necrosis factor ␣ in synovial tissues (2, 3 ) . Considering that very different autoantibodies have been shown to be associated with RA (1 ), comprehensive profiling of antigens incorporated in ICs may be effec-tive in improving our understanding; however, such studies have been very limited to date (3) (4) (5) .
In this report, we propose a novel proteomic strategy (immune complexome analysis) that entails separation of ICs from serum, direct tryptic digestion, and nano-liquid chromatography-tandem mass spectrometry for the identification and profiling of antigens in CICs. We have applied this strategy to RA as a model disease.
Serum samples were collected from RA patients (n ϭ 21; 31-84 years; 18 females) at Sasebo Chuo Hospital who fulfilled the American College of Rheumatology criteria. The mean (SD) values for disease activity scores for C-reactive protein and erythrocyte sedimentation rate in the RA patients were 3.05 (1.12) and 3.69 (1.02), respectively. Nine of 10 RA patients were positive for anti-citrulline-containing protein/peptide (anti-CCP) antibody, but the results for the other 11 patients were not available. Sera from healthy donors (n ϭ 13; 21-32 years; 9 females) and osteoarthritis patients (n ϭ 8; 45-80 years; 4 females) were collected at Nagasaki University Hospital and used as controls. Whole blood was collected into tubes containing coagulation accelerator. After removing the clot by centrifugation at 1300g for 10 min at 4°C, we stored the resulting supernatant (serum) at Ϫ80°C. All experiments were performed in accordance with the Helsinki Declaration, with approval from the institutional ethics committees.
CICs were purified by magnetic beads with immobilized protein G (PureProteome™ Protein G Magnetic Bead System; Millipore). Beads (40 L) were incubated with 10 L of serum diluted with 90 L PBS for 30 min with gentle mixing. The beads with bound ICs were recovered with a magnet and washed 3 times with 500 L PBS. The beads were resuspended in 100 L of 10 mmol/L dithiothreitol and incubated at 56°C for 45 min. We then added 100 L of 55 mmol/L iodoacetamide and incubated the mixture at room temperature for 30 min in the dark. Subsequently, we added trypsin (Promega) to a final concentration of 0.5 g/L and incubated the mixture overnight at 37°C. We then added 100 mL/L trifluoroacetic acid to stop the digestion and recovered the supernatant containing the peptide digests of antigens and antibodies. Finally, the volume of this mixture was vacuum-reduced to approximately 80 L. The peptide mixture (1 L) was subjected to nano-liquid chromatography-electrospray ionization-tandem mass spectrometry (LCQ Fleet; Thermo Fisher Scientific). The sample was loaded onto a nano precolumn [300 m (i.d.) ϫ 5.0 mm, LC-18; Chemicals Evaluation and Research Institute]. Peptides were separated on a nano-HPLC column [75 m (i.d.) ϫ 15 cm, Acclaim PepMap 100 C18, 3 m; Dionex] with gradient elution and ion spray into the mass spectrometer at a spray voltage of 1.2-2.0 kV. Tandem mass spectrometry data were searched against a human subdatabase of the public nonredundant protein database of the International Protein Index (version 3.67; European Bioinformatics Institute). The filter criteria (single-, double-, and triple-charged peptides with a correlation factor and protein probability) were adjusted by maintaining the empirically determined protein false-discovery rate at zero. More details of protein identification by nano-liquid chromatographytandem mass spectrometry can be found in the Data Supplement that accompanies the online version of this Brief Communication at http://www. clinchem.org/content/vol57/issue6.
The proteins identified by immune complexome analysis of RA patients and controls (healthy donors and osteoarthritis patients) are summarized in Table 1 . Peptides derived from IgG and keratin were ignored. Peptide assignments determined as likely to be correct on the basis of a false-discovery rate of zero were confirmed by manual verification of fragmentation spectra (Fig. 1) . Known human proteins (n ϭ 34), such as apolipoproteins, complement proteins, coagulation proteins, and adhesion proteins, were identified in more than one independent sample of RA patients. The detection of several complements (C1, C3, C4) indicated that both the extraction of ICs from serum and peptide mapping by our method were successful.
IgG and C3 have been found together on the cartilage surface (6 ), and RA-associated autoantibodies are enriched in synovial fluid (7 ) relative to serum. It is unclear, however, whether such enrichment is caused by deposition or local synthesis. Considering that CICs containing some of the antigens (clusterin, apolipoprotein E, and vitronectin) identified in this study have also been found in arthritic joints of RA and osteoarthritis patients (4 ), our results suggest that CICs possibly accumulate in lesion sites.
The best-known diagnostic marker for RA is rheumatoid factor (RF), which is bound to the Fc domain of IgG. RF has a poor specificity (80.8%) for RA (8 ) , however, and is occasionally found in healthy persons (4%) (9 ) . Anti-CCP antibody has a greater specificity (98%) for RA than RF; however, its sensitivity (68%) is lower than for RF (78.6%) (3 ), and the relevant antigens of anti-CCP antibody remain obscure (10 ) . Of the antigens we have identified, thrombospondin-1 (TSP-1) incorporated into CICs was 100% specific for RA (95% CI, 84%-100%) and appeared more sensitive (81%; 95% CI, 58%-94%) than RF and anti-CCP antibodies (Table 1, Fig. 1 ). TSP-1 has been reported to be present in synovial tissues of RA patients (11 ) , and plasma TSP-1 concentrations have been shown to be increased (12 ) . No information is available about whether TSP-1 is present in ICs, however. This report is the first to show that ICs in the sera of RA patients contain TSP-1, and the IC may be a promising marker for RA. Recent studies have suggested that the TSP-1/transforming growth factor/connective tissue growth factor pathway plays an important role in angiogenesis and erosive arthritis lesions (13, 14 ) . Although platelet factor 4 (PF4) was less sensitive (52.4%; 95% CI, 30%-75%) than TSP-1, our method also specifically detected PF4 or a variant incorporated into CICs in RA patients for the first time (Table 1, Fig.  1 ). Recently, Xiao et al. demonstrated that the ICs following the binding of anti-PF4 antibodies to PF4 were present and that they stimulated human neutrophil activation and cell adhesion (15 ) . This adhesion mechanism enables leukocytes to migrate from the blood and affect inflamed synovium. Furthermore, PF4 is known to be an angiostatic chemokine (16 ) , and the production of anti-PF4 antibodies can accelerate angiogenesis.
To investigate potential nonspecific binding of the identified proteins to the protein G beads, we spiked healthy donor sera with TSP-1 (recombinant) and PF4 (natural) at concentrations 10-fold higher than their typical concentrations in blood. Neither TSP-1 nor PF4 was recovered with the protein G beads, suggesting that their detection in the immune complexome analysis was not due to nonspecific binding and that detection of these proteins in CICs was biologically relevant.
Anti-CCP antibodies are now widely recognized as a specific marker of RA (10 ), so we also searched the mass spectra for peptides in which citrulline had been substituted for arginine; however, the detection frequency of citrullinated antigens incorporated into Data on the masses of each tryptic peptide and its fragmentation ions were compared with those predicted for all tryptic peptides from all proteins in the International Protein Index.
CICs was much lower in this study than that of noncitrullinated antigens. Similarly, other studies that used mass spectrometry reported that citrullinated peptides did not yield a better calculated fit with the fragmentation products than arginine-containing peptides in the joints of RA patients (4 ) or that citrullinated antigens were not found in the serum of RA patients (3 ) . On the other hand, some citrullinated antigens have been found in synovial fluid (3 ) or plasma (5 ) via an immunodetection method with the corresponding antibodies. The discrepancy may be attributed to the difference in methods, but it is also possible that not only citrullinated antigens but also noncitrullinated ones are involved in the pathogenesis of RA.
In conclusion, this report is the first to reveal that ICs containing TSP-1 or PF4 are present specifically in the serum of RA patients, and these ICs may have potential as alternative biomarkers for the diagnosis of RA. This method for immune complexome analysis may be generally applicable to the study of the relationship between CICs and immune response-related disease treatments in animals and humans.
